while surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (tace) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (hcc) as well as liver metastases. however, it is still not fully understood which patients particularly benefit from tace. cytokines represent a broad category of signaling molecules that might reflect concomitant inflammation as an adverse prognostic factor. here, we evaluated the role of interleukin (il)-6, il-8, andcc-chemokine ligand (ccl)22 as biomarkers in the context of tace treatment.cytokine serum levels were analyzed by multiplex immunoassay in 54 patients(hcc: n = 44, liver metastases: n = 10)undergoing tace as well as 51 healthy controls. patients with primary and secondary liver cancer showed significantly elevated levels of il-6 and il-8 but not ccl22 compared to healthy controls. interestingly, low pre-interventional levels of il-6 and il-8 were predictors for an objective response after tace in binary logistic regression. in contrast, patients with high pre-interventional il-6 and il-8 serum levels not only poorly responded to tace but had a significantly impaired overall survival. serum levels of il-6 and il-8 represent promising biomarkers for patients undergoing tace and might help to pre-interventionally identify patients who particularly benefit from tace regarding objective treatment response and overall survival.